Bank of New York Mellon’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.61M | Sell |
134,194
-6,025
| -4% | -$50K | ﹤0.01% | 3080 |
|
|
2026
Q1 | $1.18M | Sell |
140,219
-5,375
| -4% | -$56.5K | ﹤0.01% | 3110 |
|
|
2025
Q4 | $2.1M | Sell |
145,594
-4,539
| -3% | -$56.6K | ﹤0.01% | 2800 |
|
|
2025
Q3 | $1.45M | Buy |
150,133
+6,023
| +4% | +$53.3K | ﹤0.01% | 2991 |
|
|
2025
Q2 | $1.18M | Buy |
144,110
+2,710
| +2% | +$22.7K | ﹤0.01% | 3040 |
|
|
2025
Q1 | $1.01M | Sell |
141,400
-19,736
| -12% | -$147K | ﹤0.01% | 3064 |
|
|
2024
Q4 | $1.25M | Sell |
161,136
-159,253
| -50% | -$1.5M | ﹤0.01% | 3019 |
|
|
2024
Q3 | $3.36M | Sell |
320,389
-19,125
| -6% | -$233K | ﹤0.01% | 2495 |
|
|
2024
Q2 | $3.97M | Buy |
339,514
+28,846
| +9% | +$449K | ﹤0.01% | 2443 |
|
|
2024
Q1 | $6.55M | Sell |
310,668
-27,105
| -8% | -$482K | ﹤0.01% | 2184 |
|
|
2023
Q4 | $6.06M | Sell |
337,773
-22,923
| -6% | -$404K | ﹤0.01% | 2263 |
|
|
2023
Q3 | $5.94M | Sell |
360,696
-6,262
| -2% | -$113K | ﹤0.01% | 2224 |
|
|
2023
Q2 | $7.34M | Buy |
366,958
+12,075
| +3% | +$233K | ﹤0.01% | 2110 |
|
|
2023
Q1 | $6.71M | Sell |
354,883
-4,074
| -1% | -$90.1K | ﹤0.01% | 2143 |
|
|
2022
Q4 | $8.14M | Buy |
358,957
+18,901
| +6% | +$427K | ﹤0.01% | 2041 |
|
|
2022
Q3 | $8.99M | Buy |
340,056
+4,695
| +1% | +$139K | ﹤0.01% | 1957 |
|
|
2022
Q2 | $8.28M | Sell |
335,361
-9,310
| -3% | -$233K | ﹤0.01% | 2052 |
|
|
2022
Q1 | $11.4M | Buy |
344,671
+921
| +0.3% | +$25.6K | ﹤0.01% | 1994 |
|
|
2021
Q4 | $11.2M | Buy |
343,750
+4,877
| +1% | +$166K | ﹤0.01% | 2043 |
|
|
2021
Q3 | $14.2M | Buy |
338,873
+18,869
| +6% | +$679K | ﹤0.01% | 1927 |
|
|
2021
Q2 | $12.4M | Sell |
320,004
-29,129
| -8% | -$1.04M | ﹤0.01% | 2012 |
|
|
2021
Q1 | $11.9M | Buy |
349,133
+34,402
| +11% | +$1.47M | ﹤0.01% | 1993 |
|
|
2020
Q4 | $14.3M | Sell |
314,731
-8,185
| -3% | -$286K | ﹤0.01% | 1814 |
|
|
2020
Q3 | $8.89M | Sell |
322,916
-25,443
| -7% | -$829K | ﹤0.01% | 1917 |
|
|
2020
Q2 | $12.8M | Sell |
348,359
-979
| -0.3% | -$36.5K | ﹤0.01% | 1686 |
|
|
2020
Q1 | $11.3M | Sell |
349,338
-1,278
| -0.4% | -$53.2K | ﹤0.01% | 1628 |
|
|
2019
Q4 | $14.4M | Sell |
350,616
-51,321
| -13% | -$2.03M | ﹤0.01% | 1766 |
|
|
2019
Q3 | $14.3M | Sell |
401,937
-148,288
| -27% | -$6.01M | ﹤0.01% | 1726 |
|
|
2019
Q2 | $28.3M | Sell |
550,225
-120,770
| -18% | -$6.03M | 0.01% | 1333 |
|
|
2019
Q1 | $38.5M | Buy |
670,995
+140,087
| +26% | +$6.94M | 0.01% | 1130 |
|
|
2018
Q4 | $22.3M | Buy |
530,908
+171,493
| +48% | +$10.1M | 0.01% | 1401 |
|
|
2018
Q3 | $27.1M | Buy |
359,415
+40,085
| +13% | +$2.89M | 0.01% | 1427 |
|
|
2018
Q2 | $22.9M | Buy |
319,330
+186,595
| +141% | +$8.91M | 0.01% | 1519 |
|
|
2018
Q1 | $3.96M | Sell |
132,735
-4,135
| -3% | -$120K | ﹤0.01% | 2468 |
|
|
2017
Q4 | $4.55M | Sell |
136,870
-1,648
| -1% | -$49.7K | ﹤0.01% | 2401 |
|
|
2017
Q3 | $4.56M | Sell |
138,518
-38,759
| -22% | -$872K | ﹤0.01% | 2373 |
|
|
2017
Q2 | $3.5M | Buy |
177,277
+30,725
| +21% | +$595K | ﹤0.01% | 2508 |
|
|
2017
Q1 | $2.83M | Sell |
146,552
-7,593
| -5% | -$146K | ﹤0.01% | 2638 |
|
|
2016
Q4 | $2.86M | Buy |
154,145
+98,054
| +175% | +$1.87M | ﹤0.01% | 2639 |
|
|
2016
Q3 | $786K | Buy |
56,091
+12,351
| +28% | +$136K | ﹤0.01% | 3301 |
|
|
2016
Q2 | $350K | Buy |
43,740
+24,388
| +126% | +$271K | ﹤0.01% | 3683 |
|
|
2016
Q1 | $208K | Buy |
19,352
+1,077
| +6% | +$13.8K | ﹤0.01% | 3775 |
|
|
2015
Q4 | $303K | Buy |
+18,275
| New | +$363K | ﹤0.01% | 3721 |
|
Other funds holding RGNX
N
YIH
IC
Bank of New York Mellon's RGNX Position: Q2 2026 in Review
Bank of New York Mellon reduced its Regenxbio (RGNX) stake by 4.3% in Q2 2026, selling an estimated $50K and leaving 134,194 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3080.
Bank of New York Mellon first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $38.5M in Q1 2019. 67 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Bank of New York Mellon held 134,194 shares of Regenxbio worth $1.61M as of Q2 2026.
- Bank of New York Mellon sold 6,025 Regenxbio shares in Q2 2026, an estimated $50K.
- Regenxbio made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3080 holding.
- Bank of New York Mellon first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
- Bank of New York Mellon's Regenxbio position peaked at $38.5M in Q1 2019.
- 67 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.